

Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)

Technology appraisal guidance

Published: 20 December 2023

www.nice.org.uk/guidance/ta941

Contents

Advice.....	3
Information.....	3

Advice

NICE is unable to make a recommendation about the use in the NHS of ravulizumab for treating aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder. This is because Alexion Pharma UK withdrew its evidence submission for the appraisal. Alexion Pharma UK considers that the technology is unlikely to be a cost-effective use of NHS resources.

Information

If NHS organisations wish to consider ravulizumab for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-5628-9